Wednesday, February 19, 2025 | 09:56 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Zydus Cadila launches research programme to develop vaccine for coronavirus

The epidemic, which was detected last December, has claimed around 1,500 lives and infected over 66,000 people.

Zydus
Premium

Zydus Group's Vaccine Technology Centre in India, which is working on the DNA based vaccine, also has wide ranging capabilities in developing and manufacturing different vaccines for unmet needs

Vinay Umarji Ahmedabad
Ahmedabad-based pharma major Cadila Healthcare (Zydus Cadila) has announced an accelerated research programme for developing a vaccine for the novel coronavirus, (COVID-19) with multiple teams in India and Europe.  

Given the extent and rapidity of the global spread of the virus, which originated in China, the fast-tracked research programme will be based on two approaches, including development of a DNA vaccine and a live attenuated recombinant measles virus vaccine. The epidemic, which was detected last December, has claimed around 1,500 lives and infected over 66,000 people.

“There is an urgent and pressing need to develop a safe and efficacious vaccine that can

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in